{"id":"W3011921832","doi":"10.1200/jco.2012.30.15_suppl.tps4135","title":"A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Gemcitabine; Internal medicine; Gastroenterology; Progression-free survival; Pancreatic cancer; Phases of clinical research; Randomized controlled trial; Urology; Oncology; Cancer; Surgery; Clinical trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002469105,0.00306585,0.003896764,0.0005709303,0.0005812069,0.001456772,0.001407558,0.002850454,0.01024002],"category_scores_gemma":[0.002103232,0.0009958071,0.001703014,0.0005360168,0.002171585,0.001601407,0.0005254459,0.004590877,0.001902836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000892227,"about_ca_system_score_gemma":0.001562628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008575403,"about_ca_topic_score_gemma":0.001674544,"domain_scores_codex":[0.9993286,0.0003788567,0.0000268008,0.0001253364,0.00003777068,0.0001026525],"domain_scores_gemma":[0.9990131,0.0002342719,0.0002429821,0.00008544554,0.00005936655,0.0003649182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9868488,0.005022916,0.0002050688,0.0003277893,0.0003362605,0.00002333114,0.0000281882,0.0001585214,0.001345538,0.0000870259,0.0009492671,0.004667185],"study_design_scores_gemma":[0.9826096,0.01652056,0.0002294135,0.00001185816,0.00009917471,0.00001020633,0.000007436216,0.0001181058,0.0001002581,0.00006871872,0.0002193754,0.000005184063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9620413,0.0083548,0.001669397,0.002662717,0.002514618,0.01481144,0.002990557,0.000456685,0.004498505],"genre_scores_gemma":[0.9585906,0.004947826,0.003017918,0.003818703,0.001053121,0.01864055,0.002581973,0.00008210682,0.00726722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01024002,"threshold_uncertainty_score":0.03425628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1848280067776573,"score_gpt":0.4913194876446785,"score_spread":0.3064914808670213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}